$PETV

PetVivo Holdings, Inc. (PETV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

PetVivo Holdings, Inc. (PETV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 5151 Edina Industrial Blvd., Suite 575, Minneapolis, MN 55439 | (952) 405-6216 | www.petvivo.com PRESS RELEASE: Jaime Pickett Joins PetVivo Holdings, Inc. Board of Directors MINNEAPOLIS, MN, US, September 22, 2026 — PetVivo Holdings, Inc. (OTCQX: PETV) (the “Company”

Original reporting
Published Sep 22, 2026, 11:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PETV
Neutral
medium confidence
Mentioned
$PETV
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PETVNeutralLow
01

Why it matters

The board appointment is a standard corporate governance update with limited immediate financial impact.

02

Market read

Minor relevance; primarily of interest to existing shareholders and sector specialists.

03

What to watch

Dr. Pickett's extensive veterinary network could unlock new partnership opportunities not yet reflected in the stock.

Relevance 6/10Novelty 4/10Timing: effective September 22, 2026

Background

PetVivo Holdings, Inc. (OTCQX: PETV) is an emerging biomedical device company targeting companion‑animal health.

Company-level read

Ticker impact

$PETVNeutralMedium confidence
Context

PetVivo announced the appointment of Dr. Jaime K. Pickett to its Board of Directors, effective September 22, 2026.

Expected impact

minimal short‑term movement; potential modest upside if market views governance strengthening positively.

Evidence & confidence

Director appointments are routine corporate actions for micro‑caps; no material financial terms disclosed.

Market effects

May signal continued focus on veterinary‑tech sector but no broader industry shift.

Limited to US OTC market; negligible regional effect.

None

Counterpoint

Investors could view the appointment as a distraction if the board change signals internal challenges.

Key entities

  • PetVivo Holdings, Inc.

    OTCQX‑listed biomedical device firm for animal health.

  • Dr. Jaime K. Pickett

    Veterinary executive appointed to the board.

Related articles

$PETVMedAI 8/10

PetVivo Holdings Announces Transformative Acquisition Of PiezoBioMembrane To Build a Leading Functional Biomaterials Platform

PetVivo Holdings (OTCQX: PETV) said it agreed to acquire PiezoBioMembrane (PBM) via a merger, with PBM becoming a wholly owned subsidiary of Cosmeta Corp. PetVivo will issue 3,000,000 shares to PBM shareholders, with some consideration tied to milestones. The company expects PBM’s functional biomaterials and piezoelectric tech to expand IP and product development; closing is subject to customary conditions.

$HSBCLowAI 9/10

Senior notes issuance and admission to trading

HSBC Holdings plc issued EUR3.75bn in senior unsecured notes, including floating and fixed-to-floating rate notes due 2030, 2032, and 2037. The notes were listed on the FCA's Official List and admitted to trading on the London Stock Exchange's Main Market. HSBC has assets of US$3.438tn as of June 2026.

$AONMedAI 8/10

Aon plc, Aon North America, Inc., Aon Corporation, Aon Global Holdings Plc, Aon Global Limited and Aon UK Limited Enter Term Loan Credit Agreement and Revolving Credit Agreement

Aon plc and subsidiaries secured $4B in term loans and a $3B revolving credit facility from Citibank. The loans will help fund the acquisition of USI Advantage Corp. The term loans have maturities of 2028 and 2029, while the revolving credit facility matures in 2031, with optional extensions. Both agreements include financial covenants related to debt and EBITDA ratios.